Mollie VanNatta, PharmD, BCPS,BCIDP

Clinical pharmacist
Ochsner LSU Health Shreveport
Shreveport, Louisiana, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 311 - Defining the magnitude of desirability of outcome ranking (DOOR) differences in effectiveness of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)

  Friday, October 18, 2024
  10:42 AM – 10:54 AM US PT

• 312 - Impact of Patient Subgroups on the Efficacy of Ceftazidime-Avibactam (CZA) versus Ceftolozane-Tazobactam (C/T) for Multidrug-resistant (MDR) Pseudomonas aeruginosa infections in the United States (CACTUS)

  Friday, October 18, 2024
  10:54 AM – 11:06 AM US PT

• 535 - Factors affecting vancomycin and piperacillin/tazobactam-induced nephrotoxicity

  Saturday, October 19, 2024
  12:35 PM – 12:40 PM US PT